Carcinotech, a trailblazer in oncology research, has successfully raised $2,049,999 in its latest funding round, aimed at advancing its groundbreaking technology in drug discovery. As a company dedicated to transforming cancer treatment, Carcinotech has pioneered the development of assay-ready, 3D-bioprinted tumours derived directly from patient biopsies. This innovative approach ensures that the tumours maintain the intricate heterogeneity of cancer by incorporating a diverse array of cell types found in the original tumour microenvironment. This includes not only cancer cells but also stromal, immune, specialized microenvironment, and cancer stem cells, creating a more physiologically and genetically relevant model for research.
The funds raised will be instrumental in furthering their mission to enhance predictive power in oncology research by refining their bioprinted tumour models. With advantages that far surpass traditional organoid and animal models, Carcinotech's technology significantly improves the drug discovery and optimization processes, increasing pre-clinical testing efficiencies. This advancement aims to shorten the time frame necessary for bringing new oncology therapies to market, ultimately transforming patient outcomes. Carcinotech is poised to lead the charge in innovative cancer therapies, and this funding marks an exciting milestone in the company's journey. As they embark on this next phase, the team is committed to their mission of revolutionizing how drugs are tested and developed, ensuring that cancer patients benefit from the most effective treatments available as swiftly as possible.
